Abstract
A series of 19 isonicotinic acid hydrazide derivatives has been synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv using alamar blue susceptibility test. The synthesized compounds inhibit Mycobacterium tuberculosis H37Rv strain with minimum inhibitory concentration ranging from (0.00014-0.01174 mM). Among all synthesized compounds seven derivatives 2a, 2b, 2e, 2h, 2l, 2m and 2q were more potent than isoniazid and the compound 2q emerged as the most potent derivative, being more effective than isoniazid with an (MIC 0.00023 mM) in vitro. The results demonstrated the potential and importance of developing new isoniazid derivatives against Mycobacterium infections.
Keywords: Isonicotinoyl hydrazones, Mycobacterium tuberculosis H37Rv, Antitubercular activity, IR, 1H NMR, C-NMR, hydrazide Derivatives, Antitubercular Agents, Tuberculosis, Mycobacterium tuberculi, amikacin, capreomycin, HIV-1 seropositive, chemotherapy, chromosomal mutation, isonicotinoyl hydrazone
Letters in Drug Design & Discovery
Title: Synthesis, Characterization of (E)-N'-(substituted-benzylidene)isonicotinohydrazide Derivatives as Potent Antitubercular Agents
Volume: 8 Issue: 6
Author(s): Manav Malhotra, Rajiv Sharma, Vikramdeep Monga, Aakash Deep, Kapendra Sahu and Abdul Samad
Affiliation:
Keywords: Isonicotinoyl hydrazones, Mycobacterium tuberculosis H37Rv, Antitubercular activity, IR, 1H NMR, C-NMR, hydrazide Derivatives, Antitubercular Agents, Tuberculosis, Mycobacterium tuberculi, amikacin, capreomycin, HIV-1 seropositive, chemotherapy, chromosomal mutation, isonicotinoyl hydrazone
Abstract: A series of 19 isonicotinic acid hydrazide derivatives has been synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv using alamar blue susceptibility test. The synthesized compounds inhibit Mycobacterium tuberculosis H37Rv strain with minimum inhibitory concentration ranging from (0.00014-0.01174 mM). Among all synthesized compounds seven derivatives 2a, 2b, 2e, 2h, 2l, 2m and 2q were more potent than isoniazid and the compound 2q emerged as the most potent derivative, being more effective than isoniazid with an (MIC 0.00023 mM) in vitro. The results demonstrated the potential and importance of developing new isoniazid derivatives against Mycobacterium infections.
Export Options
About this article
Cite this article as:
Malhotra Manav, Sharma Rajiv, Monga Vikramdeep, Deep Aakash, Sahu Kapendra and Samad Abdul, Synthesis, Characterization of (E)-N'-(substituted-benzylidene)isonicotinohydrazide Derivatives as Potent Antitubercular Agents, Letters in Drug Design & Discovery 2011; 8 (6) . https://dx.doi.org/10.2174/157018011795906866
DOI https://dx.doi.org/10.2174/157018011795906866 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
PEGylated Dendritic Architecture for Development of a Prolonged Drug Delivery System for an Antitubercular Drug
Current Drug Delivery In Vitro Anti-mycobacterial Activity of Three Medicinal Plants of Lamiaceae Family
Recent Patents on Anti-Infective Drug Discovery Drug Evolution Concept in Drug Design: 2. Chimera Method
Medicinal Chemistry Recent Progress in Small Molecular Inhibitors of DNA Gyrase
Current Medicinal Chemistry Potential Therapeutic Agents from the Red Sea Organisms
Medicinal Chemistry Effect of Low Dose Oral Vitamin-D and Calcium Replacement in HIV Patients
Recent Patents on Anti-Infective Drug Discovery Immunoadjunctive Therapy against Bacterial Infections Using Herbal Medicines Based on Th17 Cell-mediated Protective Immunity
Current Pharmaceutical Design Clinical Applications of Choline PET/CT in Brain Tumors
Current Pharmaceutical Design Occupational Respiratory Pathology in Russia: Current Trends and Challenges
Current Respiratory Medicine Reviews Musculoskeletal Adverse Drug Reactions: A Review of Literature and Data from ADR Spontaneous Reporting Databases
Current Drug Safety Rapid Analysis of Pharmacology for Infectious Diseases
Current Topics in Medicinal Chemistry Blood Pressure Measurement: Lessons Learned from Our Ancestors
Current Pharmaceutical Design Emerging RNA-based Drugs: siRNAs, microRNAs and Derivates
Central Nervous System Agents in Medicinal Chemistry Genetic Variants of Drug Metabolizing Enzymes and Drug Transporter (ABCB1) as Possible Biomarkers for Adverse Drug Reactions in an HIV/AIDS Cohort in Zimbabwe
Current HIV Research Stroke and COVID-19 Pandemic: The Dilemma
Coronaviruses Noninvasive Assessment of Cytokines in Occupational Respiratory Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Effective Delivery Routes and Strategies for Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC)
Current Pharmaceutical Design TNF as a Target of Inflammation in Rheumatoid Arthritis
Endocrine, Metabolic & Immune Disorders - Drug Targets Macrophage Targeted Cellular Carriers for Effective Delivery of Anti-Tubercular Drugs
Recent Patents on Anti-Infective Drug Discovery Recombinant Mycobacterium bovis BCG as an HIV Vaccine Vector
Current HIV Research